Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
To verify the number of metastatic brain tumors detected in contrast-enhanced MRI, which is
the primary variable, increases after an additional dose of Magnevist (SH L 451A) comparing
images after an initial dose (0.1 mmol/kg) with those after an additional dose (0.1 mmol/kg,
a total dose of 0.2 mmol/kg) intra-individually in patients with metastatic brain tumors.
Safety was also to be assessed.